Lipid and glucose abnormalities and associated factors among children living with HIV in Asia
Submitted Date
Received Date
Accepted Date
Issued Date
2023-04-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
eISSN
20402058
Scopus ID
2-s2.0-85159242585
WOS ID
Pubmed ID
37114944
arXiv ID
Call No.
Other identifier(s)
Journal Title
Antiviral therapy
Volume
28
Issue
2
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Antiviral therapy Vol.28 No.2 (2023)
Citation
Suwanlerk T. (2023). Lipid and glucose abnormalities and associated factors among children living with HIV in Asia. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82839.
Title
Lipid and glucose abnormalities and associated factors among children living with HIV in Asia
Alternative Title(s)
Author(s)
Author's Affiliation
Siriraj Hospital
B. J. Medical College, Ahmedabad
VHS Medical Centre India
Vietnam National Children's Hospital
Children's Hospital No. 1 Ho Chi Minh City
Universitas Udayana
Universitas Indonesia
Faculty of Medicine, Chiang Mai University
The Kirby Institute
Faculty of Medicine, Khon Kaen University
Kuala Lumpur Hospital
Faculty of Medicine, Chulalongkorn University
National Centre for HIV/AIDS
Children's Hospital 2
amfAR - The Foundation for AIDS Research
Hospital Raja Perempuan Zainab II
Chiangrai Prachanukroh Hospital
Hospital Likas
Penang Hospital
B. J. Medical College, Ahmedabad
VHS Medical Centre India
Vietnam National Children's Hospital
Children's Hospital No. 1 Ho Chi Minh City
Universitas Udayana
Universitas Indonesia
Faculty of Medicine, Chiang Mai University
The Kirby Institute
Faculty of Medicine, Khon Kaen University
Kuala Lumpur Hospital
Faculty of Medicine, Chulalongkorn University
National Centre for HIV/AIDS
Children's Hospital 2
amfAR - The Foundation for AIDS Research
Hospital Raja Perempuan Zainab II
Chiangrai Prachanukroh Hospital
Hospital Likas
Penang Hospital
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
BACKGROUND: Children living with HIV (CLHIV) on prolonged antiretroviral therapy (ART) are at risk for lipid and glucose abnormalities. Prevalence and associated factors were assessed in a multicentre, Asian longitudinal paediatric cohort. METHODS: CLHIV were considered to have lipid or glucose abnormalities if they had total cholesterol ≥200 mg/dL, high-density lipoprotein (HDL) ≤35 mg/dL, low-density lipoprotein (LDL) ≥100 mg/dL, triglycerides (TG) ≥110 mg/dL, or fasting glucose >110 mg/dL. Factors associated with lipid and glucose abnormalities were assessed by logistic regression. RESULTS: Of 951 CLHIV, 52% were male with a median age of 8.0 (interquartile range [IQR] 5.0-12.0) years at ART start and 15.0 (IQR 12.0-18.0) years at their last clinic visit. 89% acquired HIV perinatally, and 30% had ever used protease inhibitors (PIs). Overall, 225 (24%) had hypercholesterolemia, 105 (27%) low HDL, 213 (58%) high LDL, 369 (54%) hypertriglyceridemia, and 130 (17%) hyperglycemia. Hypercholesterolemia was more likely among females (versus males, aOR 1.93, 95% CI 1.40-2.67). Current PIs use was associated with hypercholesterolemia (current use: aOR 1.54, 95% CI 1.09-2.20); low HDL (current use: aOR 3.16, 95% CI 1.94-5.15; prior use: aOR 10.55, 95% CI 2.53-43.95); hypertriglyceridemia (current use: aOR 3.90, 95% CI 2.65-5.74; prior use: aOR 2.89, 95% CI 1.31-6.39); high LDL (current use: aOR 1.74, 95% CI 1.09-2.76); and hyperglycemia (prior use: aOR 2.43, 95% CI 1.42-4.18). CONCLUSION: More than half and one-fifth of CLHIV have dyslipidemia and hyperglycemia, respectively. Routine paediatric HIV care should include metabolic monitoring. The association between PIs use and dyslipidemia emphasizes the importance of rapidly transitioning to integrase inhibitor-containing regimens.